keyword
MENU ▼
Read by QxMD icon Read
search

Biomarkers in Psychiatry

keyword
https://www.readbyqxmd.com/read/28640591/managing-psychotropic-medications-in-complex-real-world-patients-using-comprehensive-therapeutic-drug-monitoring
#1
Jeffrey J Sutherland, Ryan D Morrison, J Scott Daniels, Stephen B Milne, Timothy P Ryan
There are multiple treatment options for depression, anxiety, psychosis, and other psychiatric disorders, and psychiatry patients are often comorbid with complex, polypharmacy treatment regimens. Unlike cardiovascular disease and diabetes, there are no readily available biomarkers to gauge treatment success with psychotropic medications, often resulting in subjective determination of medication therapy effectiveness. The physiochemical properties of psychiatric medications in general lend themselves to quantitative measurement in blood, offering an avenue to optimize treatment for each patient...
June 22, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/28600276/data-collection-for-mental-health-studies-through-digital-platforms-requirements-and-design-of-a-prototype
#2
Talayeh Aledavood, Ana Maria Triana Hoyos, Tuomas Alakörkkö, Kimmo Kaski, Jari Saramäki, Erkki Isometsä, Richard K Darst
BACKGROUND: Mental and behavioral disorders are the main cause of disability worldwide. However, their diagnosis is challenging due to a lack of reliable biomarkers; current detection is based on structured clinical interviews which can be biased by the patient's recall ability, affective state, changing in temporal frames, etc. While digital platforms have been introduced as a possible solution to this complex problem, there is little evidence on the extent of usability and usefulness of these platforms...
June 9, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28596125/biomarkers-in-psychiatry-between-myth-and-clinical-reality
#3
J Javier Meana, Irene Mollinedo-Gajate
No abstract text is available yet for this article.
June 5, 2017: Revista de Psiquiatrí́a y Salud Mental
https://www.readbyqxmd.com/read/28574009/potential-biomarkers-for-bipolar-disorder-where-do-we-stand
#4
REVIEW
Rajesh Sagar, Raman Deep Pattanayak
Bipolar disorder (BD) is a severe, recurrent mood disorder, associated with a significant morbidity and mortality, with high rates of suicides and medical comorbidities. There is a high risk of mood disorders among the first-degree relatives of patients with BD. In the current clinical practice, the diagnosis of BD is made by history taking, interview and behavioural observations, thereby lacking an objective, biological validation. This approach may result in underdiagnosis, misdiagnosis and eventually poorer outcomes...
January 2017: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/28497736/-implication-of-human-endogenous-retroviruses-in-schizophrenia-and-bipolar-disorder
#5
Pierre Ellul, Laurent Groc, Marion Leboyer
Schizophrenia and bipolar disorder are neuropsychiatric disorders of unknown origin. It seems that these two disorders share some common etiopathogenic mechanisms including genetic, environmental and inflammatory ones. Reactivation of the human endogenous retrovirus type W (HERV-W) can be a shared element in the pathophysiology of schizophrenia and bipolar disorder, linked to immuno-genetic and environment risk factors. We will present studies that have highlighted the presence of HERV-W in schizophrenic and bipolar disorder patients...
April 2017: Médecine Sciences: M/S
https://www.readbyqxmd.com/read/28488297/frailty-in-older-adults-with-amnestic-mild-cognitive-impairment-as-a-result-of-alzheimer-s-disease-a-comparison-of-two-models-of-frailty-characterization
#6
Natália O C Cezar, Rafael Izbicki, Diego Cardoso, Jouce G Almeida, Leandro Valiengo, Marina V Z Camargo, Orestes V Forlenza, Monica S Yassuda, Ivan Aprahamian
AIM: To verify the prevalence and presence of frailty markers, and their relationship to cognitive function among older adults with amnestic mild cognitive impairment (aMCI). METHODS: This was an observational study with transversal analyses. Older adults with aMCI as a result of Alzheimer's disease (n = 40) were compared with healthy controls (n = 26) at the Psychogeriatric Outpatient Unit, Institute and Department of Psychiatry, Faculty of Medicine of the University of São Paulo...
May 10, 2017: Geriatrics & Gerontology International
https://www.readbyqxmd.com/read/28439103/brain-age-predicts-mortality
#7
J H Cole, S J Ritchie, M E Bastin, M C Valdés Hernández, S Muñoz Maniega, N Royle, J Corley, A Pattie, S E Harris, Q Zhang, N R Wray, P Redmond, R E Marioni, J M Starr, S R Cox, J M Wardlaw, D J Sharp, I J Deary
Age-associated disease and disability are placing a growing burden on society. However, ageing does not affect people uniformly. Hence, markers of the underlying biological ageing process are needed to help identify people at increased risk of age-associated physical and cognitive impairments and ultimately, death. Here, we present such a biomarker, 'brain-predicted age', derived using structural neuroimaging. Brain-predicted age was calculated using machine-learning analysis, trained on neuroimaging data from a large healthy reference sample (N=2001), then tested in the Lothian Birth Cohort 1936 (N=669), to determine relationships with age-associated functional measures and mortality...
April 25, 2017: Molecular Psychiatry
https://www.readbyqxmd.com/read/28403846/the-new-field-of-precision-psychiatry
#8
Brisa S Fernandes, Leanne M Williams, Johann Steiner, Marion Leboyer, André F Carvalho, Michael Berk
BACKGROUND: Precision medicine is a new and important topic in psychiatry. Psychiatry has not yet benefited from the advanced diagnostic and therapeutic technologies that form an integral part of other clinical specialties. Thus, the vision of precision medicine as applied to psychiatry - 'precision psychiatry' - promises to be even more transformative than in other fields of medicine, which have already lessened the translational gap. DISCUSSION: Herein, we describe 'precision psychiatry' and how its several implications promise to transform the psychiatric landscape...
April 13, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28358316/theranostic-biomarkers-for-schizophrenia
#9
REVIEW
Matea Nikolac Perkovic, Gordana Nedic Erjavec, Dubravka Svob Strac, Suzana Uzun, Oliver Kozumplik, Nela Pivac
Schizophrenia is a highly heritable, chronic, severe, disabling neurodevelopmental brain disorder with a heterogeneous genetic and neurobiological background, which is still poorly understood. To allow better diagnostic procedures and therapeutic strategies in schizophrenia patients, use of easy accessible biomarkers is suggested. The most frequently used biomarkers in schizophrenia are those associated with the neuroimmune and neuroendocrine system, metabolism, different neurotransmitter systems and neurotrophic factors...
March 30, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28353229/the-utility-of-multiplex-assays-for-identification-of-proteomic-signatures-in-psychiatry
#10
Junfang Chen, Paul C Guest, Emanuel Schwarz
As substantial efforts are being made to identify biological markers of psychiatric illnesses, it is becoming clear that clinically useful accuracy will require larger sets of readouts that potentially span different technological platforms. For discovery of proteomic biomarkers, simultaneous measurement of analytes in small sample quantities has developed into a widely used technology of similar quality as the respective single-plex assays. Multiplex assay systems therefore hold promise for biomarker discovery and development in many complex disease areas including psychiatry...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28344933/precision-medicine-the-golden-gate-for-detection-treatment-and-prevention-of-alzheimer-s-disease
#11
H Hampel, S E O'Bryant, J I Castrillo, C Ritchie, K Rojkova, K Broich, N Benda, R Nisticò, R A Frank, B Dubois, V Escott-Price, S Lista
During this decade, breakthrough conceptual shifts have commenced to emerge in the field of Alzheimer's disease (AD) recognizing risk factors and the non-linear dynamic continuum of complex pathophysiologies amongst a wide dimensional spectrum of multi-factorial brain proteinopathies/neurodegenerative diseases. As is the case in most fields of medicine, substantial advancements in detecting, treating and preventing AD will likely evolve from the generation and implementation of a systematic precision medicine strategy...
December 2016: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/28286989/a-precision-medicine-initiative-for-alzheimer-s-disease-the-road-ahead-to-biomarker-guided-integrative-disease-modeling
#12
REVIEW
H Hampel, S E O'Bryant, S Durrleman, E Younesi, K Rojkova, V Escott-Price, J-C Corvol, K Broich, B Dubois, S Lista
After intense scientific exploration and more than a decade of failed trials, Alzheimer's disease (AD) remains a fatal global epidemic. A traditional research and drug development paradigm continues to target heterogeneous late-stage clinically phenotyped patients with single 'magic bullet' drugs. Here, we propose that it is time for a paradigm shift towards the implementation of precision medicine (PM) for enhanced risk screening, detection, treatment, and prevention of AD. The overarching structure of how PM for AD can be achieved will be provided through the convergence of breakthrough technological advances, including big data science, systems biology, genomic sequencing, blood-based biomarkers, integrated disease modeling and P4 medicine...
April 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28282077/-endophenotypes-in-psychiatry
#13
Salvador M Guinjoan
We review the concept of endophenotype, and its relationship with related terms in use in the scientific literature, including "biomarker" and "intermediate phenotype". We then explain the importance of the concept in current psychiatry research. Specifically, we focus in the potential importance of endophenotypes in both disentangling the genetic causes, and improving the dimensional and pathophysiologic definition, of psychiatric nosological categories. After delineating which types of variables could constitute valid endophenotypes, we describe efforts in defining neurobiological signatures of social cognitive deficits in schizophrenia as an example with potential heuristic value...
September 2016: Vertex: Revista Argentina de Psiquiatriá
https://www.readbyqxmd.com/read/28236993/-what-role-for-paraclinical-investigations-within-clinical-trials-conducted-in-psychiatric-patients
#14
A Kaladjian, M Adida, N Simon, R Belzeaux, O Blin, E Fakra, J-M Azorin
As in the usual care of patients, paraclinical investigations have today only a very modest role in clinical trials in psychiatry, mainly to complete the pre-therapeutical assessments prior to inclusion of subjects or to monitor treatment tolerance. Yet, the accumulation of data in neurosciences suggests the next emergence of biomarkers, whose interest is that they are closely associated to the biological disturbances underlying psychiatric illnesses, and that they are accessible by means of technological tools such as imaging devices...
December 2016: L'Encéphale
https://www.readbyqxmd.com/read/28236988/-what-can-we-expect-from-clinical-trials-in-psychiatry
#15
A Marsot, Q Boucherie, F Kheloufi, C Riff, D Braunstein, J Dupouey, R Guilhaumou, X Zendjidjian, S Bonin-Guillaume, E Fakra, M Guye, V Jirsa, J-M Azorin, R Belzeaux, M Adida, J Micallef, O Blin
Clinical trials in psychiatry allow to build the regulatory dossiers for market authorization but also to document the mechanism of action of new drugs, to build pharmacodynamics models, evaluate the treatment effects, propose prognosis, efficacy or tolerability biomarkers and altogether to assess the impact of drugs for patient, caregiver and society. However, clinical trials have shown some limitations. Number of recent dossiers failed to convince the regulators. The clinical and biological heterogeneity of psychiatric disorders, the pharmacokinetic and pharmacodynamics properties of the compounds, the lack of translatable biomarkers possibly explain these difficulties...
December 2016: L'Encéphale
https://www.readbyqxmd.com/read/28131433/the-effect-of-mindfulness-meditation-training-on-biological-acute-stress-responses-in-generalized-anxiety-disorder
#16
Elizabeth A Hoge, Eric Bui, Sophie A Palitz, Noah R Schwarz, Maryann E Owens, Jennifer M Johnston, Mark H Pollack, Naomi M Simon
Mindfulness-Based interventions have increased in popularity in psychiatry, but the impact of these treatments on disorder-relevant biomarkers would greatly enhance efficacy and mechanistic evidence. If Generalized Anxiety Disorder (GAD) is successfully treated, relevant biomarkers should change, supporting the impact of treatment and suggesting improved resilience to stress. Seventy adults with GAD were randomized to receive either Mindfulness-Based Stress Reduction (MBSR) or an attention control class; before and after, they underwent the Trier Social Stress Test (TSST)...
January 25, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28130814/serum-tumour-necrosis-factor-%C3%AE-and-interleukin-6-levels-in-alzheimer-s-disease-and-mild-cognitive-impairment
#17
Yo Sup Kim, Kang Joon Lee, Hyun Kim
BACKGROUND: Neuroinflammation has been recognized as a feature of Alzheimer's disease (AD), and mild cognitive impairment (MCI) is believed to share several pathological features with AD. The aim of the present study was to compare serum cytokine levels between patients with AD, subjects with MCI, and healthy controls, and to assess the correlation between cytokine levels and cognitive performance in these subjects. METHODS: Participants included 35 patients with AD, 29 subjects with MCI, and 28 healthy controls from the Department of Psychiatry of IIlsan Paik Hospital in South Korea...
January 28, 2017: Psychogeriatrics: the Official Journal of the Japanese Psychogeriatric Society
https://www.readbyqxmd.com/read/28115739/genome-wide-association-study-of-therapeutic-opioid-dosing-identifies-a-novel-locus-upstream-of-oprm1
#18
A H Smith, K P Jensen, J Li, Y Nunez, L A Farrer, H Hakonarson, S D Cook-Sather, H R Kranzler, J Gelernter
Opioids are very effective analgesics, but they are also highly addictive. Methadone is used to treat opioid dependence (OD), acting as a selective agonist at the μ-opioid receptor encoded by the gene OPRM1. Determining the optimal methadone maintenance dose is time consuming; currently, no biomarkers are available to guide treatment. In methadone-treated OD subjects drawn from a case and control sample, we conducted a genome-wide association study of usual daily methadone dose. In African-American (AA) OD subjects (n=383), we identified a genome-wide significant association between therapeutic methadone dose (mean=68...
March 2017: Molecular Psychiatry
https://www.readbyqxmd.com/read/28093569/translational-evaluation-of-translocator-protein-as-a-marker-of-neuroinflammation-in-schizophrenia
#19
T Notter, J M Coughlin, T Gschwind, U Weber-Stadlbauer, Y Wang, M Kassiou, A C Vernon, D Benke, M G Pomper, A Sawa, U Meyer
Positron emission tomography (PET) imaging with radiotracers that target translocator protein 18 kDa (TSPO) has become a popular approach to assess putative neuroinflammatory processes and associated microglia activation in psychotic illnesses. It remains unclear, however, whether TSPO imaging can accurately capture low-grade inflammatory processes such as those present in schizophrenia and related disorders. Therefore, we evaluated the validity of TSPO as a disease-relevant marker of inflammation using a translational approach, which combined neurodevelopmental and neurodegenerative mouse models with PET imaging in patients with recent-onset schizophrenia and matched controls...
January 17, 2017: Molecular Psychiatry
https://www.readbyqxmd.com/read/28093567/beta-amyloid-sequelae-in-the-eye-a-critical-review-on-its-diagnostic-significance-and-clinical-relevance-in-alzheimer-s-disease
#20
REVIEW
T M Shah, S M Gupta, P Chatterjee, M Campbell, R N Martins
Alzheimer's disease (AD) is a progressive and fatal neurodegenerative disorder. There is no test for its definitive diagnosis in routine clinical practice. Although phase III clinical trials have failed, only symptomatic treatment is currently available; a possible reason for these failed trials is that intervention commenced at an advanced stage of the disease. The hallmarks of an AD brain include plaques comprising of extracellular beta-amyloid (Aβ) protein aggregates and intracellular hyperphosphorylated neurofibrillary tangles of tau...
March 2017: Molecular Psychiatry
keyword
keyword
7315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"